ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Trading Down 0.1 %

Shares of NASDAQ AVBP traded down $0.02 during mid-day trading on Friday, reaching $19.52. 374,084 shares of the company's stock were exchanged, compared to its average volume of 159,053. The firm has a market capitalization of $663.99 million, a price-to-earnings ratio of -7.60 and a beta of 1.00. The business has a fifty day simple moving average of $24.92 and a 200 day simple moving average of $26.72. ArriVent BioPharma has a twelve month low of $14.35 and a twelve month high of $36.37.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on AVBP shares. B. Riley initiated coverage on ArriVent BioPharma in a research report on Thursday. They set a "buy" rating and a $37.00 price target on the stock. Guggenheim initiated coverage on ArriVent BioPharma in a report on Monday, March 10th. They set a "buy" rating and a $45.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $39.00 price objective on shares of ArriVent BioPharma in a report on Friday, March 7th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $39.00.

Remove Ads

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.